Inspire Medical Systems (NYSE:INSP) Shares Gap Down Following Analyst Downgrade
by Teresa Graham · The Cerbat GemInspire Medical Systems, Inc. (NYSE:INSP – Get Free Report)’s stock price gapped down before the market opened on Friday after Bank of America downgraded the stock from a neutral rating to an underperform rating. The stock had previously closed at $44.74, but opened at $42.89. Bank of America now has a $39.00 price target on the stock. Inspire Medical Systems shares last traded at $43.1350, with a volume of 226,925 shares traded.
A number of other research analysts have also recently weighed in on INSP. Truist Financial reduced their price target on shares of Inspire Medical Systems from $64.00 to $50.00 and set a “hold” rating on the stock in a research report on Tuesday, May 5th. Mizuho reduced their price target on shares of Inspire Medical Systems from $70.00 to $55.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 5th. JPMorgan Chase & Co. reduced their price target on shares of Inspire Medical Systems from $67.00 to $54.00 and set a “neutral” rating on the stock in a research report on Tuesday, May 5th. Stifel Nicolaus reduced their price target on shares of Inspire Medical Systems from $70.00 to $65.00 and set a “buy” rating on the stock in a research report on Tuesday, May 5th. Finally, Weiss Ratings cut shares of Inspire Medical Systems from a “sell (d+)” rating to a “sell (d)” rating in a research report on Wednesday, May 6th. Four analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $81.84.
Read Our Latest Stock Analysis on INSP
Institutional Trading of Inspire Medical Systems
A number of hedge funds have recently made changes to their positions in the company. Wellington Management Group LLP bought a new stake in shares of Inspire Medical Systems in the fourth quarter worth $203,929,000. Wasatch Advisors LP increased its stake in shares of Inspire Medical Systems by 7.2% in the second quarter. Wasatch Advisors LP now owns 1,634,395 shares of the company’s stock worth $212,095,000 after buying an additional 110,288 shares during the last quarter. William Blair Investment Management LLC increased its stake in shares of Inspire Medical Systems by 68.7% in the third quarter. William Blair Investment Management LLC now owns 1,297,573 shares of the company’s stock worth $96,280,000 after buying an additional 528,404 shares during the last quarter. Morgan Stanley increased its stake in shares of Inspire Medical Systems by 179.5% in the fourth quarter. Morgan Stanley now owns 1,259,762 shares of the company’s stock worth $116,188,000 after buying an additional 809,121 shares during the last quarter. Finally, Deerfield Management Company L.P. increased its stake in shares of Inspire Medical Systems by 648.4% in the third quarter. Deerfield Management Company L.P. now owns 1,047,694 shares of the company’s stock worth $77,739,000 after buying an additional 907,694 shares during the last quarter. Hedge funds and other institutional investors own 94.91% of the company’s stock.
Inspire Medical Systems Stock Down 4.0%
The business’s 50 day moving average is $51.93 and its 200-day moving average is $76.52. The firm has a market cap of $1.24 billion, a P/E ratio of 9.56, a price-to-earnings-growth ratio of 4.56 and a beta of 0.83.
Inspire Medical Systems (NYSE:INSP – Get Free Report) last issued its quarterly earnings results on Monday, May 4th. The company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.38. The business had revenue of $204.58 million during the quarter, compared to analyst estimates of $200.04 million. Inspire Medical Systems had a net margin of 14.33% and a return on equity of 10.35%. The business’s revenue was up 1.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.10 earnings per share. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. As a group, equities analysts predict that Inspire Medical Systems, Inc. will post 0.91 earnings per share for the current year.
Inspire Medical Systems Company Profile
Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.
The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.